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DOI 10.1016/j.ccr.2011.10.001SUMMARYCyclin D-dependent kinases (CDK4 and CDK6) are positive regulators of cell cycle entry and they are over-
active in the majority of human cancers. However, it is currently not completely understood by which cellular
mechanisms CDK4/6 promote tumorigenesis, largely due to the limited number of identified substrates. Here
we performed a systematic screen for substrates of cyclin D1-CDK4 and cyclin D3-CDK6. We identified the
Forkhead Box M1 (FOXM1) transcription factor as a common critical phosphorylation target. CDK4/6 stabi-
lize and activate FOXM1, thereby maintain expression of G1/S phase genes, suppress the levels of reactive
oxygen species (ROS), and protect cancer cells from senescence. Melanoma cells, unlike melanocytes, are
highly reliant on CDK4/6-mediated senescence suppression, which makes them particularly susceptible to
CDK4/6 inhibition.INTRODUCTION
Excessive cell proliferation induced by aberrant entry into the cell
cycle is considered a hallmark of cancer. Commitment to cell
cycle entry occurs during the G1 phase, when CDK4 and
CDK6 form active complexeswith one of the three D-type cyclins
(D1, D2, or D3). These complexes promote G1-S transition in
cancer cells by phosphorylating critical substrates, of which
the Retinoblastoma tumor suppressor protein, RB1, as well as
the related family members, RBL1 (p107) and RBL2 (p130),
remain best characterized. Mechanistically, phosphorylation
of RB proteins disables their function as transcriptional repres-
sors to allow activation of the E2F-dependent transcriptionalSignificance
CDK4/6 catalytic activity is thought to be critically required for
itors, such as PD0332991, are currently under way. Even so, th
geted by CDK4/6. This information is not only critical for our
cancer, but may also aid in optimizing current therapeutic s
CDK4/6 substrates across the human proteome. Our analyse
signaling might be an effective strategy to enforce senesce
CDK4/6 should be tested in clinical trials against malignant m
620 Cancer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Incprogram, an important mediator of S-phase entry and initiation of
DNA synthesis (Ortega et al., 2002; Sherr and Roberts, 1999).
These processes are negatively regulated by INK4 proteins
(including p15INK4B and p16INK4A), which specifically inhibit the
assembly and activation of cyclin D-CDK4/6 complexes.
It is therefore not surprising that CDK4 and its regulatory
subunit, cyclin D1, are oncogenes; and recent findings have
revealed that both are embedded in the ten most frequently
amplified genomic loci in a diverse set of human cancers (Berou-
khim et al., 2010). Conversely, the gene encoding p16INK4A
exhibits more deletions than any other recessive cancer gene
(Bignell et al., 2010). Moreover, cyclin D1-CDK4 is required for
the formation of several tumor types, including breast and lungtumorigenesis, and clinical trials with small molecule inhib-
ere is little information about the spectrum of substrates tar-
understanding of cell cycle control and its deregulation in
trategies. In this study we have assembled a resource of
s suggest that therapeutic targeting of CDK4/6/ FOXM1
nce in cancer cells, and that small molecule inhibitors of
elanoma.
.
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critically important (Yu et al., 2006; Landis et al., 2006; Puyol
et al., 2010).
Despite of this, the full spectrum of the substrates phosphor-
ylated by CDK4/6 remains unknown, although this information
is crucial for our understanding of kinase function in human
cancer. It is also unclear whether individual cyclin D1/D2/D3-
CDK4/6 complexes target the same subset of proteins for phos-
phorylation, or whether they possess distinct substrate specific-
ities. Yet, linking CDK4/6 to their substrates is particularly
challenging; unlike other CDKs, CDK4 and CDK6 are not readily
susceptible to chemical genetics approaches, using ‘‘bulky’’
adenosine triphosphate (ATP). Classical substrate-trapping
methods also pose inherent limitations, such as the transient
nature of physical kinase-substrate interactions, the general
difficulty to detect low-abundance proteins, and the experi-
mental restriction of the analysis to certain cell or tissue types.
Here we sought to overcome these limitations, and to uncover
genuine substrates of CDK4/6 across the human proteome.
Through functional analysis of substrate phosphorylation we
aim to define mechanisms by which CDK4/6 promote tumori-
genesis in order to maximize the merits of CDK4/6 small
molecule inhibitors for targeted therapy.
RESULTS
Cyclin D-CDK4/6 Substrate Phosphorylation Profiling
In Vitro and in Cells
Our strategy for substrate identification was to use computa-
tional tools to enrich for candidate substrates from the entire
human proteome, and then to experimentally test the enriched
proteins for phosphorylation in high-throughput kinase reac-
tions, using individual cyclin D-CDK4/6 complexes. CDKs
possess exquisite phosphorylation site selectivity, with the
phosphate-acceptor residue preceding a proline. Moreover,
the so-called ‘‘full’’ CDK consensus site typically contains one
or more basic residues downstream of the critical proline
(Songyang et al., 1994). In keeping with this, we searched the
SWISSPROT protein database with the web-based program
Scansite (Obenauer et al., 2003) for human nuclear proteins
containing at least two CDK consensus sites. We did not
include proteins with only one site, due to previous observations
that CDKs phosphorylate their substrates preferentially on
multiple sites (Ubersax et al., 2003). This in silico analysis led
to the identification of 445 candidate protein-coding genes
(Figure 1A).
We reasoned that like RB proteins, purified putative sub-
strates would become phosphorylated by recombinant cyclin
D-CDK4/6 in in vitro assays. This approach excludes indirect
phosphorylation events and makes use of the firmly established
in vitro substrate selectivity of CDK4 in particular (Sherr and
Roberts, 1999). We successfully expressed and purified 285
candidate proteins (see Table S1 available online), correspond-
ing to 231 genes, from Escherichia coli and challenged them
individually with either cyclin D1-CDK4 or cyclin D3-CDK6
complex, as these are the most characterized. All obtained
relative protein phosphorylation scores (PR-scores) were plotted
on a scale normalized to phosphorylation of RB1, and the
PR-score was set to 100% (Figure 1B). For detailed informationCanof the PR scores of all tested proteins see Table S1. To define
in vitro substrates, a cut-off of 20% was applied; this threshold
can be considered conservative, as it does not take into account
RB1’s many phosphorylation sites (substrates phosphorylated
at only two sites might be expected to have lower PR-scores
than those phosphorylated at 10 sites, for example). However,
we did not include such calculation in our analysis, as it assumes
that phosphorylation of each site is equally efficient, but this
scenario is unlikely and difficult to assess experimentally. Impor-
tantly, all three RB family members scored as substrates in both
screens (Figure 1B). By contrast, histone proteins, which repre-
sent substrates of all CDKs, except cyclin D-CDK4/6 (Sherr
and Roberts, 1999), were not phosphorylated, further confirming
the specificity of our analysis. Intriguingly, we discovered major
differences in substrate phosphorylation between the two
kinases, with cyclin D3-CDK6 possessing a much broader
substrate specificity than cyclin D1-CDK4 (Figure 1B). In total,
our screen revealed 13 common in vitro substrates, including
RB1, RBL1, and RBL2, 53 CDK6-D3 preferred, and only 5
CDK4-D1 preferred in vitro substrates (Figure 1C; see Figure S1A
for all substrate PR scores).
To validate at least some of the proteins in human cells, all 71
in vitro substrates were expressed in HEK293 cells. Although, in
many cases, phosphorylation of proteins does not result in
changes in their electrophoretic migration on SDS gels
(CDK4/6-mediated phosphorylation of RBL1 is an example),
eight proteins (RB1, RBL2, SENP3, MEF2D, SRrp35, ZEB1,
SHOX2, FOXM1) showed reproducible mobility shifts with coex-
pression of the kinases, but not with kinase-inactive CDK
versions (Figure 1D; Figure S1B). Concordantly, short-term treat-
ment (40 min) with a CDK4/6 specific inhibitor, PD0332991 (Fry
et al., 2004), abrogated the CDK-induced mobility shifts (Fig-
ure 1E). Further, the differences in in vitro substrate phosphor-
ylation specificity of cyclin D1-CDK4 versus cyclin D3-CDK6
were largely recapitulated in cells (Figure 1D; Figure S1B).
Together, this underscores the feasibility of our in vitro screening
approach.
Cyclin D-CDK4/6 Activate FOXM1
Transcriptional Function
We noted with interest that many of the 71 in vitro substrates
share a transcription regulatory function (Figure 1F). Such
proteins are often underrepresented in traditional proteomic
approaches that rely on mass spectrometry, due to their low
abundance in cells. The FOXM1 transcription factor was chosen
for further investigation for several reasons. First, FOXM1 was
in vitro phosphorylated by cyclin D1-CDK4 and cyclin
D3-CDK6 equally well, thus defining it as a universal CDK4/6
substrate (Figure S1A). Second, FOXM1 was among the in vivo
validated phosphorylation targets as assessed by mobility shift
analysis (Figure 1D). Third, some of its biological functions over-
lap with those regulated by CDK4/6 activity, such as the positive
regulation of the cell cycle transition from G1 to S phase (Wang
et al., 2002, 2008), suppression of cellular senescence (Wang
et al., 2005; Park et al., 2009), and maintenance of pancreatic
b-cell mass in vivo (Ackermann and Gannon, 2007). Fourth, like
CDK4/6, FOXM1 is critically required for tumorigenesis, as
observed for several cancer types (Kalinichenko et al., 2004;
Liu et al., 2006).cer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Inc. 621
Figure 1. Proteome-Wide Identification of CDK4/6 Substrates
(A) A schematic diagram to illustrate the approach for substrate identification. All nuclear proteins with at least two potential CDK phosphorylation sites were
selected from the protein database SWISS-PROT. Candidate proteins were expressed in E. coli, purified, and tested for phosphorylation by recombinant cyclin
D1-CDK4 and cyclin D3-CDK6. Reaction products were analyzed by SDS-PAGE (lower panel) and autoradiography (upper panel), and relative rates of
phosphorylation (PR scores) were calculated.
(B) Side-by-side comparison of phosphorylation of 285 enriched proteins by cyclin D3-CDK6 (upper panel) versus cyclin D1-CDK4 (lower panel). PR scores are
the rates of phosphorylation normalized to RB1, which was set to 100%. Proteins with PR scores >20% are referred to as in vitro substrates. Arrows indicate
histone proteins; the three RB family proteins are highlighted in red.
(C) Overlap between cyclin D1-CDK4 (blue circle) and cyclin D3-CDK6 (red circle) in vitro substrates.
(D) In vitro substrates were coexpressed in HEK293 cells with either empty vector (EV) or wild-type cyclin-CDK complexes (left panel). Coexpression of wild-type
versus kinase-dead (KM) CDK versions is shown in the middle panel. Phosphorylated SHOX2 was treated with calf intestinal phosphatase (CIAP, right panel).
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Figure 2. Cyclin D-CDK4/6 Activate FOXM1 Transcriptional Function
(A) Effects of individual and combined expression of FOXM1 and cyclin D-CDK4/6 complexes on reporter gene activation (±SD). HeLa cells were transfected with
the CCNG2, TSC22D1, IGFBP-1, 6DB, CENPF and PLK1 promoter-luciferase constructs, FOXM1 (M1), empty vector (), cyclin D1-CDK4 (14), or cyclin
D3-CDK6 (36).
(B) Reporter activity (±SD) in HeLa cells after transfection of FOXM1 (M1) and cyclin D1-CDK4 (14), or cyclin D3-CDK6 (36), versus kinase-dead (KM) versions.
(C) U2OS cells stably expressing either control (sh-con) or RB1 targeting shRNA (sh-RB1) were transfected with the CCNG2 promoter-reporter, empty vector (EV,
blue) or FOXM1 (pink), and treated with DMSO, 0.1 mM or 1 mM PD0332991 for 16 hr. Values are mean ±SD.
(D) RB1 protein expression in control (sh-con) and RB1 knockdown (sh-RB1) cells.
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Cyclin D-CDK/FOXM1 Signaling Suppresses SenescenceWe first examined whether CDK4/6 alters the ability of FOXM1
to activate transcription. To this end, promoters derived from
several FOXM1 target genes, the common Forkhead-responsive
IGF-binding protein 1 (IGFBP1) promoter, and the 6DB sequence
containing six tandemForkhead-response elements, were trans-
fectedwith or without FOXM1, and in the presence or absence of
cyclin D1-CDK4 or cyclin D3-CDK6. Figure 2A illustrates that
coexpression of the kinases in RB protein-deficient HeLa cells
markedly potentiated FOXM1-mediated transcription from all(E) Collapse in the mobility shift of seven CDK4/6 substrates upon short-term
tagged substrates plus cyclin D-CDK complexes were expressed in HEK293
transfection.
(F) ‘‘Biological process’’ gene ontology (GO) terms were assigned to all 71 in vitr
Cantested promoters, whereas expression of the kinases without
FOXM1 had much less effect. Moreover, activation of transcrip-
tion required CDK4 and CDK6 catalytic activity (Figure 2B).
Conversely, inhibition of endogenous CDK4/6 activity with the
specific inhibitor, PD0332991, reduced FOXM1-mediated tran-
scription in both, control shRNA and RB1 shRNA expressing
U2OS cells (Figure 2C), in which the RB1 protein was reduced
to undetectable levels (Figure 2D). Thus, CDK4/6 can drive
FOXM1-mediated transcription in the absence of RB1.treatment (40 min) with the CDK4/6 specific inhibitor, PD0332991. GST-
cells exposed to either 1 mM of the inhibitor (PD) or DMSO () 30 hr post-
o substrates. See also Figure S1 and Table S1.
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Figure 3. Contribution of CDK Consensus Sites to FOXM1 Transcriptional Function
(A) Arrangement of Scansite CDK motifs in FOXM1. S4 (asterisks) is a typical S/T-P CDK site, but is not detected by Scansite, due to its close proximity to the N
terminus. FH, Forkhead domain; TAD, transactivation domain.
(B) Reporter gene activation (±SD) in U2OS cells transfected with the 6DB luciferase plasmid plus either empty vector (EV), the FOXM1 15 site to alanine mutant
(‘‘15A’’), FOXM1 ‘‘add-back’’ mutants or wild-type FOXM1 (WT). All add-back (A/ S/T) mutated residues are highlighted in red; mutant alanines are not shown.
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by Multisite Phosphorylation
The data presented in Figures 1 and 2 indicate that CDK4/6 posi-
tively regulate FOXM1 activity by direct phosphorylation. FOXM1
harbors 5 RXL (cyclin binding) motifs and 15 CDK consensus
sites, 12 of which are localized in its C-terminal transactivation
domain (TAD) (Figure 3A). We first systematically determined
the relative contribution of each of the 15 consensus sites, as
well as combinations thereof, to FOXM1 transcriptional activity
(Figure 3B). We then asked which of the sites are targeted by
CDK4/6 (Figure 4). Compound mutation of all 15 sites to alanines
led—like CDK4/6 inhibitor treatment (Figure 2C)—to greatly
diminished FOXM1 transcriptional activity in U2OS cells (Fig-
ure 3B). We then introduced a series of ‘‘add-back’’ (A/ S/T)
mutations into this template. As illustrated in Figure 3B, no single
phosphorylation site was sufficient to mediate transactivation,
nor was any tested combination of two or three sites. However,624 Cancer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Incserial reconstitution of five to seven sites in the FOXM1 C
terminus, comprising T600, T611, T620, T627, S638, S672,
and S704, progressively increased transcription, consistent
with the observation that T600, T611, and T638 critically
contribute to FOXM1 function (Laoukili et al., 2008b). By
contrast, A/ S/T replacements of an equal number of residues
localized in the FOXM1 N-terminal and middle region, spanning
S4, S35, S451, S489, S508, T510, and S522, did not lead to
transactivation. Nevertheless, restoration of all 12 TAD sites
(from S451 to S704) resulted in full activation. Thus, phosphory-
lation of the C-terminal region of the TAD domain is pivotal for
driving transcription.
Endogenous FOXM1 was phosphorylated in U2OS cells by
cyclin D3-CDK6 in a kinase-dependent fashion as judged by
mobility shift analyses (Figure 4A). Of note, previous studies
have shown that FOXM1 is phosphorylated in vivo on at least
nine S/T-P CDK consensus sites (Laoukili et al., 2008b). To.
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geted sites in vivo, we turned to quantitative mass spectrometry,
and sought to obtain site-specific phosphorylation quantification
rather than absolute FOXM1 sequence coverage. As shown in
Figure 4B and Figure S2A, there were two in vivo CDK4/6 phos-
phorylation sites in the FOXM1 N terminus, and at least three in
the C-terminal region of the TAD, which is consistent with the
finding that phosphorylation of this region is critical for FOXM1
function (Figure 3B). Importantly, phosphorylation at S4, S35,
T611, and T620 was specifically induced by exogenous cyclin
D3-CDK6 catalytic activity in HeLa cells (Figure 4C), although
this analysis is limited by the basal phosphorylation state of indi-
vidual sites in vivo, as some may be inherently phosphorylated
by endogenous CDK activity. Phosphorylation quantification of
T627 did not reach statistical significance, but in vivo phosphor-
ylation of S35 was further confirmed by mobility shift analysis of
a truncated FOXM1 protein (DTAD), which only contains the
N-terminal CDK4/6 target sites and three RXL motifs (Figure 4D).
As illustrated in Figure 4E, coexpression of cyclin D3-CDK6 led
to decreased DTAD electrophoretic mobility, which specifically
required S35 and CDK6 catalytic activity (Figure 4F). Moreover,
FOXM1’s N-terminal RXL motifs 1 and 2, but not motif 3 in the
FH domain (Figure 4G), are involved in CDK6-mediated phos-
phorylation of S35, which fits the observation that RXL
sequences may allow for efficient phosphorylation of CDK sites
lacking basic residues (Figure S2C) (Leng et al., 2002).
Direct FOXM1 multisite phosphorylation by CDK4/6 was
further confirmed in in vitro assays. When three FOXM1 frag-
ments covering the entire protein sequence were incubated
with recombinant cyclin D3-CDK6 complex and subjected to
mass spectrometry, there were 10 in vitro phosphorylated sites,
although S35 and S638 were not susceptible to analysis (Fig-
ure 4H; Figure S2B). Notably, most in vitro sites are localized in
the TAD (Figure 4H), and the FOXM1 fragments comprising the
TAD were phosphorylated by cyclin D1-CDK4 and cyclin
D3-CDK6 in in vitro assays (Figure 4I). Accordingly, mutation of
all 10 phosphorylation sites within the TAD plus S638 to alanine
(the ‘‘11A’’ mutant) greatly diminished FOXM1 activation by
CDK4 and CDK6 (Figure 4J). Finally, compound mutation of
all RXL motifs in the N terminus and the TAD did not affect
CDK4/6-mediated activation of FOXM1 (Figures S2D and S2E).
Thus, although RXL sequences aid in phosphorylation of certain
sites, such as S35, they are not required for FOXM1 activation. In
sum, these data identify five overlapping in vivo and in vitro
CDK4/6 target sites in FOXM1 (S4, S35, T611, T620, and
T627), although the phosphorylation site coverage of our in vivo
analysis was only fragmentary. We conclude that multisite phos-
phorylation of the FOXM1 C terminus by CDK4/6 is required for
full activation of FOXM1 transcriptional function.
We next sought to obtain a FOXM1 phosphomimetic mutant,
which should remain active under conditions of acute CDK4/6
inhibition. When we progressively replaced all S/T-P CDK
consensus sites in the TAD with aspartic acid residues, there
was an increase in overall FOXM1-mediated transcription (Fig-
ure 4K), although to a much lesser extent than was the case
upon coexpression of wild-type FOXM1 with cyclin D-CDK4/6
(Figure 2A). Notably, aspartic acid has only a single negative
charge, so more aspartic acid residues may be needed than
phosphates to efficiently activate FOXM1. Most importantly,Canhowever, although PD0332991 treatment substantially dimin-
ished the function of wild-type FOXM1 (by 70%), the reduction
was much less when transcription was driven by the FOXM1
‘‘12D’’ mutant (Figure 4L). Thus, a multisite phosphorylation
mechanism, which activates FOXM1by converting its C-terminal
domain into an acidic-type TAD, is highly plausible.
Cyclin D-CDK4/6 Stabilize the FOXM1 Protein
by Multisite Phosphorylation
We next asked whether cyclin D-CDK4/6 activity also regulates
the expression of FOXM1 itself. To this end, we treated a large
panel of human cancer cell lines with the specific CDK4/6 inhib-
itor, PD0332991. We noted with interest that CDK4/6 inhibition
partially to completely ablated expression of the FOXM1 protein,
with the most dramatic effects seen in human melanoma cell
lines (Figure 5A). By contrast, inhibition of CDK2 had no such
effect (Figure S3A). We next explored the mechanism by which
PD0332991 decreased FOXM1 levels. Importantly, this mecha-
nism was independent of RB1, as FOXM1 expression was still
efficiently reduced in RB1 knockdown cells (Figures 5B and
2D). Moreover, when FOXM1was expressed from a constitutive,
but weak promoter (that is used here throughout Figure 5) in
U2OS cells, it became apparent that PD0332991 treatment
reduced endogenously as well as exogenously expressed
FOXM1 protein to a comparable extent (left panel of Figure 5A
versus 5C). Conversely, when cyclin D-CDK complexes were
ectopically expressed in HeLa cells with or without FOXM1,
they upregulated both exogenously as well as endogenously
expressed FOXM1 protein (Figure 5D). By contrast, when
FOXM1 was expressed at much higher levels using CMV-based
plasmids, the total protein amount barely changed in response to
either CDK4/6 inhibition or ectopic expression (Figure S3B; see
also Figures 3 and 4). This is understandable, as the relative
reduction of the protein by PD0332991 becomes negligible
under these conditions.
Because these results suggested a posttranscriptional mech-
anism of regulation, we next asked whether cyclin D-CDK4/6
activity interferes with FOXM1 protein degradation. Indeed,
treatment of U2OS cells with a proteasomal inhibitor, MG132,
blocked PD0332991-induced FOXM1 turnover (Figure 5E). Like-
wise, ablation of the anaphase-promoting complex (APC)
subunit CDH1, a mediator of FOXM1 proteasomal degradation
(Laoukili et al., 2008a), partially protected this transcription factor
from proteolysis (Figure 5F).
We finally examined if FOXM1 protein turnover is regulated by
phosphorylation of FOXM1 itself. To address this, we took
advantage of FOXM1 phosphomimetic mutants, harboring
replacements of either the N-terminal CDK4/6 target sites
(S4D/S35D), the 12 TAD CDK sites (12D), or all 14 CDK sites,
including S4/S35 (the ‘‘14D mutant’’). As illustrated in Figure 5G,
‘‘simulated’’ multisite phosphorylation of the 12 TAD or all 14
sites partially protected FOXM1 from drug-induced degrada-
tion. Degradation susceptibility of FOXM1 S4D/S35D was less
reduced, with a rank order of wild-type FOXM1 > S4D/S35D >
12D = 14D. This suggests that multisite phosphorylation
converts FOXM1 to a more degradation-resistant state, in addi-
tion to activating its transcriptional function. Such a mechanism
is indirectly supported by the observation that FOXM1 protein
expression is induced at the end of G1 (Major et al., 2004),cer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Inc. 625
Figure 4. CDK4/6 Activate FOXM1 by Multisite Phosphorylation
(A) Immunoprecipitation (IP) of endogenous FOXM1 fromU2OS cells expressing either empty vector (EV), cyclin D3-CDK6, or cyclin D3 and kinase-inactive CDK6
(CDK6KM).
(B and C) FOXM1 was coexpressed with either empty vector (), or cyclin D3 and CDK6 (36), or cyclin D3 and kinase-inactive CDK6KM (36KM) in HeLa cells,
immunoprecipitated and subjected to quantitative mass spectrometry. In vivo phosphorylated sites are depicted in red; black sites were not accessible to
analysis; no phosphorylation was detected on blue sites. Site-specific in vivo phosphorylation quantification (±SD) is shown in (C).
(D) FOXM1 TAD deletion mutant (DTAD) with N-terminal CDK4/6 sites (red).
(E) HeLa cells were cotransfected with either empty vector (), or cyclin D3 and CDK6 (36), plus FOXM1DTAD wild-type (WT) or phosphorylation-site mutants
(S4A, S35A, S331A).
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Figure 5. CDK4/6 Stabilize FOXM1 by Multisite Phosphorylation
(A) U2OS and melanoma cells (red) were incubated with DMSO or 1 mM PD0332991 (PD) for 16 hr, and endogenous FOXM1 protein levels were analyzed.
(B) U2OS cells stably expressing either control (sh-con) or RB1 targeting shRNA (sh-RB1) were treated with PD0332991 and endogenous FOXM1 was analyzed.
(C) U2OS cells were transfected with pBABE empty vector (EV) or pBABE-FOXM1 and treated with PD0332991.
(D) Cells were cotransfected with either pBABE empty vector (EV) or pBABE-FOXM1, and cyclin D1-CDK4 (14) or cyclin D3-CDK6 (36). Expression of the
HA-tagged cyclins is shown below.
(E) U2OS cells transfected with pBABE-FOXM1 were treated with 5 mM MG132 (MG) 4 hr prior to cell lysis.
(F) U2OS cells were transfected with pBABE-FOXM1 and either control (si-con) or CDH1 siRNA (si-CDH1).
(G) Effect of replacing the FOXM1 N-terminal (S4/S35), 12 TAD, or all 14 CDK (12 TAD plus N-terminal) sites with aspartic acid residues on FOXM1 protein levels.
U2OS cells were transfected with either pBABE wild-type FOXM1 (WT), FOXM1 S4/S35 to D (S4D/S35D), ‘‘12D’’ or ‘‘14D’’ mutant. Cells were treated with DMSO
() or 1 mM PD0332991 (PD) for 16 hr. See also Figure S3.
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maximally active.
CDK4/6/ FOXM1 Signaling Suppresses Senescence
in Cancer Cells
It is currently not completely understood how hyperactive cyclin
D-CDK4/6 promote tumorigenesis. One possible mechanism is(F) FOXM1DTAD cotransfections with either empty vector (), or cyclin D3 and C
(G) Cotransfections with either empty vector (), or cyclin D3 andCDK6 (36), and F
replaced by AXA.
(H) FOXM1 fragments (black bars) were in vitro phosphorylated by cyclin D3-CDK6
red; unphosphorylated sites are blue; black sites were not accessible to analysis
(I) In vitro phosphorylation assay performed using recombinant cyclin D1-CDK4 o
histone H2A. P32, autoradiogram; AB, Amidoblack protein staining for total prote
(J) Activation of the 6DB promoter (±SD) by wild-type FOXM1 (M1) versus the ‘‘1
D3-CDK6 (36, right panel). Protein expression is shown (lower panel).
(K) Effect of phosphomimetic mutations on FOXM1 transcriptional activity (±SD). H
wild-type FOXM1 (WT), or phosphomimeticmutants (S/T residue numbers replace
(L) U2OS cells transfectedwith the 6DBpromoter and either empty vector (EV), wil
or 1 mM PD0332991 (PD) for 16 hr. Values are mean ±SD. See also Figure S2.
Canto overcome cellular senescence, a permanent form of growth
arrest that is normally enforced in cells by aberrant oncogenic
signaling and that prevents them from progressing toward
malignancy (Campisi and d’Adda di Fagagna, 2007).
We have previously shown that cyclin D1-CDK4 catalytic
activity is critically required in a murine model of HER2-driven
breast cancer (Yu et al., 2006; Landis et al., 2006).We now askedDK6 (36), or cyclin D3 and kinase-inactive CDK6KM (36KM).
OXM1DTADwild-type (WT) or RXLmutant versions, in which the RXLmotif was
and analyzed bymass spectrometry. Phosphorylated residues are depicted in
.
r cyclin D3-CDK6 with RB1, FOXM1 middle (M) or C-terminal fragment (C), and
in amounts.
1A’’ CDK site to alanine mutant plus cyclin D1-CDK4 (14, left panel) or cyclin
eLa cells were transfected with the 6DB promoter and either empty vector (EV),
d by aspartic acid, blue). Expression of themutant proteins is shown in the inlet.
d-type FOXM1 (WT) or the FOXM1 ‘‘12D’’mutant (12D) were treatedwith DMSO
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Figure 6. Inhibition of CDK4/6 Catalytic Activity Enforces a ROS Dependent Senescence Program by Disabling FOXM1
(A) Percentage of SA-b-galactosidase positive cells (±SD) among breast cancer (V720), osteosarcoma (U2OS), and melanoma (SKMEL2) cell lines, each treated
with either DMSO or 500 nM PD0332991 for 8 days.
(B and C) Immunofluorescence staining of U2OS cells (B) and SKMEL2 cells (C) using anti-trimethyl K9 histone H3 antibody (K9M-H3, upper panel) or DAPI (lower
panel). Cells were treated with either DMSO or PD0332991 as above. Scale bar represents 10 mm.
(D and E) Quantification of cellular granularity by FACS. Side scatter (SSC) analysis of U2OS (D) and SKMEL2 cells (E), treated with either DMSO or 500 nM
PD0332991 as above. Graphs are from triplicate experiments.
(F and G) Percentage of SA-b-galactosidase positive U2OS cells upon knockdown of CDK4/6 (F) and FOXM1 (G). Cells were transiently transfected with the
indicated siRNAs, followed by 8-day PD0332991 treatment starting 48 hr posttransfection. si-con, control siRNA; si-CDK4, CDK4-specific siRNA; si-CDK6,
CDK6-specific siRNA; si1-FOXM1 and si2-FOXM1, two different siRNAs targeting FOXM1. The asterisk indicates an unspecific band.
(H) Wild-type (WT) and FOXM1 knockout MEFs (FOXM1/) were transduced with either pBABE empty vector (EV), wild-type FOXM1 (WT) or the 11-site
phosphorylation mutant (11), and FOXM1 expression was analyzed (right panel; asterisks indicate unspecific bands). Cells were treated with either DMSO or
100 mM of the ROS inducing drug, Imexon. SA-b-galactosidase positive cells were counted after 4 days of treatment. Error bars, SD; *p < 0.05, **p < 0.01.
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cells) with PD0332991 ‘‘reactivates’’ the senescence program.
We also examined the effects of treatment of human osteosar-
coma (U2OS) and melanoma cells (SKMEL2). As shown in Fig-
ure 6A, acute inhibition of CDK4/6 increased the activity of
SA-b-Gal, a marker for senescent cells, in all three cell lines,
whereas inhibition of CDK2 had only marginal effects (Fig-
ure S4A). Other markers of senescence were also detectable,
such as global chromatin modifications, including tri-methylated
lysine 9 of histone H3 (K9M3-H3; Figures 6B and 6C), and
a dramatic increase in overall cellular granularity (Figures 6D
and 6E).
Importantly, initiation of this senescence program was not
merely a consequence of cell cycle inhibition by PD0332991
(Figures S4B–S4D). Moreover, like CDK4/6 inhibitor treatment,
siRNA-mediated knockdown of CDK4 and CDK6 in combination
led to a significant increase in basal senescence, although to
a lesser extent (Figure 6F). These results are consistent with
previous observations that genetic ablation of CDK4 leads to
the induction of cellular senescence (Zou et al., 2002; Puyol
et al., 2010). Surprisingly, however, PD0332991-triggered
senescence is partially RB1-independent, as depletion of this
bona fide substrate in U2OS cells decreased senescence by
<50% (Figures S4E–S4G). This observation led us to examine
whether FOXM1 is involved in CDK4/6-mediated senescence
suppression. Of note, FOXM1 is a transcriptional activator, and
the effects of its depletion on senescence are therefore opposite
to those of ablation of RB1, which acts as transcriptional
repressor. Thus, although RB1 ablation decreased basal senes-
cence (Figure S4E), transfection of U2OS cells with two different
FOXM1 siRNAs resulted in a substantial increase in basal senes-
cence (from 1.5% to 14% and 9%, respectively). Importantly,
FOXM1 knockdown did not further enhance PD0332991-
induced SA-b-Gal activity (Figure 6G).
To further substantiate the involvement of FOXM1, we recon-
stituted FOXM1 knockout MEFs (Laoukili et al., 2005) with wild-
type FOXM1 or the inactive ‘‘11’’ site mutant (Figure 4J). As
immortalized FOXM1 knockout MEFs show only a modest
increase in senescence (approximately 5%), we challenged
both cell populations with the reactive oxygen species (ROS)-
inducing drug, Imexon (ROS are known to induce senescence).
Although Imexon increased absolute SA-b-Gal activity in
FOXM1 knockout cells expressing an empty vector (EV), it barely
did so in thewild-type cells (Figure 6H). Importantly, reexpression
of wild-type FOXM1, but not the inactive 11 phosphorylation site
mutant, significantly lowered Imexon-induced SA-b-Gal activity.
Conversely, when we expressed constitutively active FOXM1
(the 12D phosphomimetic mutant) in U2OS cells and quantified
SA-b-Gal activity following treatment with PD0332991, the
senescence response was reduced by 36% (Figure 6I). By
contrast, there were no significant differences between cells
transfected with empty vector or wild-type FOXM1 (Figure 6I).(I) SA-b-galactosidase positive U2OS cells (±SD) transfected with either empty vec
promoter). Cells were treated as in (F). Error bars, SD; *p < 0.05, **p < 0.01.
(J) Measurement of cytoplasmic ROS levels with carboxy-H2DCFDA by FACS in
(K) Quantification of mitochondrial ROS levels with MitoSOX red in U2OS cells tr
(L) SA-b-galactosidase positive U2OS cells (±SD) after simultaneous incubation
Figure S4.
CanTaken together, these data strongly suggest that CDK4/6 phos-
phorylate FOXM1 to protect cells from senescence, consistent
with previous findings of FOXM1 exhibiting senescence-sup-
pressing activity (Wang et al., 2005), presumably by repressing
the levels of ROS (Park et al., 2009). Notably, elevated ROS
levels were detectable in the cytoplasm and mitochondria of
U2OS cells as early as 3 days post-PD0332991 treatment, and
they further increased with time (Figures 6J and 6K). Concor-
dantly, when ROS were scavenged by treatment of U2OS cells
with an antioxidant, N-acetyl-cysteine (NAC), PD0332991-
induced senescence was abrogated (Figure 6L).
CDK4/6/ FOXM1 Signaling Induces Expression
of Critical G1/S Genes and Promotes S Phase Entry
We also monitored the early transcriptional response to acute
inhibition of CDK4/6 catalytic activity. As PD0332991 substan-
tially induced senescence in U2OS cells and HER2-overex-
pressing mouse mammary tumor cells (V720, Figure 6A), we
hypothesized that the identification of overlapping genes exhib-
iting differential expression in both cell lines (human osteosar-
coma and mouse breast cancer) would uncover ‘‘common’’
CDK4/6 regulated genes potentially contributing to senescence
regulation, rather than cell type-specific transcriptional changes.
We therefore performed gene expression arrays in combination
with QPCR analysis from U2OS and V720 cells treated with or
without PD0332991 for 4 hr. Although this did not result in signif-
icant changes in the cell cycle profile (Figure S5), it led to a
significant decrease in the expression of 19 common genes
(Figures 7A and 7B).
Expectedly, several of those genes, including cyclin E1 and
E2, are known to be induced at the G1/S phase transition and
have previously been identified as transcriptional targets of the
canonical RB-E2F pathway (Bracken et al., 2004). To test the
involvement of FOXM1 in the regulation of these 19 genes, we
compared their expression in wild-type and FOXM1 knockout
MEFs, each expressing either empty vector (EV) or constitutively
active CDK4R24C. As illustrated in Figure 7C, CDK4 expression
substantially increased (>1.75-fold) the mRNA levels of 9 out of
19 genes in the wild-type cells. However, none of the genes
were induced in the absence of FOXM1, indicating that this
transcription factor positively regulates expression of G1/S
phase genes like cyclin E2 (CCNE2), MYB, MCM2, MCM10,
and CDT1, which are critical for initiation of DNA replication,
but also activates genes involved in the regulation of DNA repair
(XRCC2) and mRNA splicing (SFRS4). Accordingly, ectopic
expression of FOXM1 induced transcription of a representative
panel of PD0332991-regulated genes, including cyclin E2,
MSH6, and SKP2, an established FOXM1 target gene (Wang
et al., 2005) (Figure 7E). Moreover, the induction of cyclin E,
MSH6, and MYB was blunted during G1/S transition in FOXM1
knockout MEFs (Figure 7G). Concordantly, these cells had
a delay in S phase entry (Figure 7F), which fits previoustor (EV), wild-type FOXM1 (WT), or the ‘‘12D’’ mutant (expressed from the CMV
U2OS cells treated with either DMSO or 500 nM PD0332991 for 3 and 6 days.
eated as in (J).
with 1 mM N-acetyl-cysteine (NAC) and either DMSO or PD0332991. See also
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Figure 7. FOXM1 Activates Key G1/S Genes Downstream of CDK4 Function and Promotes G1/S Transition
(A and B) Nineteen ‘‘common’’ cyclin D-CDK4/6-regulated genes obtained by microarray analysis from U2OS cells (A), and QPCR analysis (±SD) from V720
mouse mammary tumor cells (B). Each cell line was treated with either DMSO or PD0332991 for 4 hr. For each cell line, genes are arranged from the highest to
lowest change in expression.
(C) QPCR analysis of the indicated genes in wild-type (WT) and FOXM1/MEFs, each stably expressing either pBABE empty vector (EV) or CDK4R24C (CDK4).
Values derived from WT-EV cells were set to 1-fold change in expression. Values are mean ± SD.
(D) Protein expression of HA-tagged CDK4R24C and endogenous CDK4 (CDK4endo) in wild-type (WT) and FOXM1/ MEFs.
(E) U2OS cells were transfected with the indicated promoter-luciferase constructs plus either empty vector or FOXM1. Reporter assay results are visualized as
a heat map (scale, right panel).
(F and G) Wild-type (WT) and FOXM1/ MEFs were serum starved for 48 hr, followed by serum addition for the indicated times. Cell cycle parameters (F) and
mRNA expression (G) were subsequently assessed by FACS and QPCR analysis (±SD), respectively. See also Figure S5.
Cancer Cell
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et al., 2002, 2008).
PD0332991 Triggers Massive Senescence in Malignant
Melanoma Cells, But Not in Normal Melanocytes
The strong reduction of the FOXM1 protein in malignant mela-
noma cell lines (Figure 5A) and the dramatic senescence630 Cancer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Incresponse triggered by PD0332991 in SKMEL2 melanoma cells
(Figures 6A, 6C, and 6E) prompted us to investigate whether
this senescence induction is common among cell lines derived
from this tumor type, which is notoriously known for its chemo-
resistance. It was also unclear whether PD0332991 elicits similar
effects in ‘‘normal’’ melanocytes. As shown in Figure 8A, the drug
triggered profound senescence in all tested human melanoma.
Figure 8. PD0332991-Induced Cellular
Senescence Is Linked to CDK4Hyperactiva-
tion and the Transformed Phenotype
(A) Percentage of SA-b-galactosidase positive
(±SD) primary melanocytes versus malignant
melanoma cells following treatment with
PD0332991 or DMSO for 8 days.
(B and C) Successive transduction (top to bottom)
of primary melanocytes with hTERT, CDK4R24C,
dominant-negative p53 (p53DD), BRAFV600E, and
MITF renders these cells susceptible to
PD0332991-induced senescence. (B) Percentage
of SA-b-galactosidase positive cells (±SD)
following PD0332991 or DMSO treatment for
8 days. (C) Trimethylation of histone H3 lysine 9
(K9M-H3) is visualized by immunofluorescence
(red). Nuclear DNA was stained with DAPI (blue).
Scale bar represents 10 mm.
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Cyclin D-CDK/FOXM1 Signaling Suppresses Senescencecell lines (in addition to SKMEL2, Figure 6A), but not in the
primary human melanocytes derived from four different donors.
Moreover, when these PD0332991-unresponsive melanocytes
were transformed by serial introduction of common melanoma
oncogenes, including CDK4R24C, BRAFV600E, and MITF as previ-
ously described (Garraway et al., 2005), only the fully trans-
formed cells showed a substantial drug-induced senescence
response, as judged by the increase in SA-b-Gal activity (Fig-
ure 8B) and histone H3 lysine 9 trimethylation (Figure 8C). By
comparison, transduction of constitutively active CDK4
(CDK4R24C) had only a moderate effect, indicating that hyperac-Cancer Cell 20, 620–634, Ntivation of this kinase is a prerequisite but
not sufficient event in rendering melano-
cytes fully susceptible to CDK4/6 inhib-
itor-induced senescence.
DISCUSSION
Identification of CDK4/6 Substrates
by Combined Approaches
We performed an unbiased systematic
substrate screen for CDK4 and CDK6,
and generated a list of 68 potential human
phosphorylation targets, in addition to the
three RB family proteins (Figure S1). This
in vitro substrate resource is not confined
to proteins expressed in certain cell,
organ, tissue or tumor types, and can be
used as a basis for future analyses of
CDK4/6 molecular functions in a wide
variety of developmental and disease
processes, ranging from cancer to
diabetes.
Several general findings emerged from
our combinatorial screen. First, there is
considerable difference in substrate
specificity between the cyclin D1-CDK4
and cyclin D3-CDK6 complex, with the
latter phosphorylating a much broader
spectrum of substrates. A strikingexample is the potent in vitro phosphorylation of splicing regula-
tory proteins, such as SFRS16, TRA2A, SFRS10, by cyclin D3/
CDK6, but not cyclin D1/CDK4 (Figure S1). Second, phosphory-
lation of substrates by CDK4/6 can induce protein stabilization,
as shown here for FOXM1 (Figure 5). Notably, we did not observe
such stabilization under conditions of strong (CMV promoter-
driven) ectopic substrate expression, which overrides the subtle
effects of CDK-induced protein stabilization (Figure S3B). Thus,
from our validation screen, it is not possible at present to esti-
mate the proportion of substrates stabilized by phosphorylation.
Third, in addition to inactivating transcriptional repressors likeovember 15, 2011 ª2011 Elsevier Inc. 631
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by phosphorylation, thereby driving specific gene expression.
Although our substrate screen is unbiased, it is clear that the
number of in vitro substrates presented here is an underestima-
tion of the total number of potential phosphorylation targets in
the entire human proteome. Our computational substrate
enrichment analysis was based on two assumptions: the poten-
tial substrates bear at least two CDK consensus sites, and they
possess the annotation keyword ‘‘nuclear’’ in their SWISSPROT
protein entry. There will be cases where genuine substrates
have only one CDK motif, and where protein database-listed
annotations are not correctly defined (proteins can extensively
shuttle between cytoplasm and nucleus, and might not be cate-
gorized as nuclear in annotation analysis). Further, our current
ORFeome library is not complete, and some proteins are not
susceptible to expression in E. coli. Together, these limitations
reduced the number of proteins subjected to the screen. In addi-
tion, our in vivo substrate validation method by mobility shift
analysis is not applicable to all identified in vitro substrates.
Thus, although our combined screening approach revealed
eight confirmed substrates (SENP3, MEF2D, SRrp35, ZEB1,
SHOX2, FOXM1, RB1, RBL2), the real number is likely to be
substantially higher.
CDK4/6 Regulate FOXM1 Activity and Stability
by Multisite Phosphorylation
FOXM1 is a master regulator of the cell cycle, being required for
timely entry into both S phase and mitosis (Figure 7E) (Wang
et al., 2002, 2008; Laoukili et al., 2005). Phosphorylation of
FOXM1 starts in G1, and continues during S, G2 and M phases
of the cell cycle (Major et al., 2004). The data presented here
suggest that CDK4/6 initiate FOXM1 phosphorylation, thereby
causing accumulation of this transcription factor in cells. At the
same time, phosphorylation directly activates FOXM1 transcrip-
tional function, consistent with previous observations that cyclin
D1-CDK4 strongly activates FOXM1 in reporter gene assays
(Wierstra and Alves, 2006), as does cyclin E-CDK2, although to
a lesser extent (Lu¨escher-Firzlaff et al., 2006). It is plausible
that the coexistence of these two regulatory mechanisms (stabi-
lization and activation) provides CDK4/6 with a more powerful
and elaborate control over transcription factor function than
would either mechanism alone.
How is FOXM1 activated in cancer cells by CDK4/6-mediated
phosphorylation? It is clear from Figure 3B that seven C-terminal
phosphorylation sites, spanning T600 to S704, critically
contribute to FOXM1 function. Moreover, there is a direct corre-
lation between the number of accessible CDK sites in this
C-terminal region and FOXM1 transcriptional function, suggest-
ing that CDKs activate this transcription factor according to
a quantitative model, which would allow to ‘‘fine-tune’’ FOXM1
function to spatial and temporal gradients of CDK activity. Based
on the data presented in Figure 3, it is likely that phosphorylation
simply incorporates negative charge into the C-terminal TAD,
thereby progressively activating FOXM1, possibly by relieving
autorepression by the N-terminal domain (Laoukili et al., 2008b).
CDKs have not previously been implicated in FOXM1 protein
stabilization, although this is an important aspect of FOXM1
regulation (Figure 5A). FOXM1 degradation is mediated through
three degradation (D) boxes and one KEN box, all of which632 Cancer Cell 20, 620–634, November 15, 2011 ª2011 Elsevier Incare localized in the FOXM1 N terminus (Laoukili et al.,
2008a). Although CDK4/6 phosphorylate the N-terminal sites,
S4 and S35 in vivo (Figure 4C), phosphomimetic mutations at
these two sites were not sufficient to protect FOXM1 from
PD0332991-induced degradation (Figure 5G). Indeed, the data
suggest that phosphorylation of more sites in the TAD is required
to efficiently stabilize FOXM1 (Figure 5G). Thus, we favor the idea
that multisite phosphorylation, concomitantly with conferring
transcriptional activation, converts FOXM1 to a more proteol-
ysis-resistant conformation by making the degradation boxes
less accessible to CDH1 (Figures 5F, 5G).
It has been shown that CDK2 phosphorylates FOXM1 (Laoukili
et al., 2008b), yet inhibition of CDK2 did not change the steady-
state level of this transcription factor (Figure S3A) and did not
cause senescence in U2OS and SKMEL2 cells (Figure S4A),
which is in sharp contrast to the consequences of inhibition of
CDK4/6 (Figure 6). Moreover, the critical requirement of CDK4/6
for tumor formation makes them the most likely candidate ki-
nases to account for increased FOXM1 function in many tumors,
such as HER2-positive breast cancers, in which expression of
HER2 and FOXM1 are tightly correlated (Francis et al., 2009).
FOXM1 and RB1
Although RB1 is considered the major substrate of cyclin
D-dependent kinases, emerging evidence indicates that
CDK4/6/ RB1 signaling does not mediate all CDK4/6 catalytic
functions (this study; Dean et al., 2010; Haferkamp et al., 2008). It
is important to note that much of the experimental evidence
describing RB1 as the central cyclin D-CDK4/6 substrate stems
from the analysis of RB1-negative cell lines, in which CDK4/6
inhibition had no phenotypic consequences. However, RB1-
negative cancer cell lines, such as HeLa, ‘‘overexpress’’
p16INK4A and therefore lack functional cyclin D-CDK4/6
complexes, as the CDK4/6 subunits form stable binary
complexes with p16INK4A (Ruas and Peters, 1998). This makes
the interpretation of the data obtained from RB1-negative cells
difficult.
To overcome this limitation by outcompeting p16INK4A, we
overexpressed D-type cyclins together with the CDK4/6 subunit
in HeLa cells (Figures 3A and 3B). Using this cell line, we demon-
strated that CDK4/6 activate FOXM1 independently of RB
proteins (Figure 2). It was recently reported that FOXM1 activa-
tion by CDK4 is lost in RB1-negative cells, but these findings
rest on the expression of FOXM1 fragments lacking the
N-terminal repression domain (Wierstra and Alves, 2006).
Although we do not exclude the possibility that additional mech-
anisms contribute to the regulation of FOXM1 function, and that
RB1 may play a role in this process, the data presented here
strongly suggest that CDK4/6 activate and stabilize FOXM1 by
direct phosphorylation.
CDK4/6 Substrate Phosphorylation
and Senescence Suppression
Senescence is a tumor-suppressive mechanism, and it must
be overcome during cell immortalization and transformation.
Indeed, CDK4/6 overactivation is a common hallmark of human
cancers, and ectopic expression of both kinases substantially
extends the proliferative lifespan of primary cells, such as human
fibroblasts (Ruas et al., 2007). Several of our identified in vitro.
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Cyclin D-CDK/FOXM1 Signaling Suppresses Senescencesubstrates (Figure S1), including FOXM1, MYC, and ZEB1, were
shown to suppress cellular senescence (Wu et al., 2007; Liu
et al., 2008). It is therefore likely that CDK4/6 maintain senes-
cence suppression through phosphorylation of several tran-
scriptional regulators, including RB1 and FOXM1. This might,
in fact, explain why FOXM1 knockdown triggers senescence in
only 9%–14% of U2OS cells (Figure 6G), as compared to
approximately 25%–30% induced by acute inhibition of CDK4/6
with PD0332991 in the same cell type (Figure 6F). In melanoma
cells, PD0332991-induced senescence was markedly higher,
indicating that cells derived from this tumor type are particularly
reliant on senescence suppression by CDK4/6 catalytic activity
(Figure 8). Importantly, this reliance likely rests on a combination
of signals emanating from several oncogenes, such as BRAF and
MITF (in addition to CDK4). These findings provide a rationale for
the treatment of melanoma with small molecule inhibitors of
CDK4/6.EXPERIMENTAL PROCEDURES
In Silico Screen of the Human Proteome
The UniProtKB/SWISS-PROT protein database was searched for CDK-motif
containing protein sequences using Scansite 2.0 (Obenauer et al., 2003).
Homo sapiens was chosen as ‘‘single species,’’ and the keyword ‘‘nucleus’’
was specified to enrich for nuclear proteins. Detailed information can be found
in the Supplemental Experimental Procedures.High-Throughput Protein Expression in E. coli and Purification
Bacterial protein expression and cell lysis was performed according to Braun
et al. (2002). GST fusion proteins were enriched and purified with a ME200 12
channel electronic pipetter equipped with 20 ml Glutathione PhyTip columns
(Phynexus).Phosphorylation Quantification and PR-Score Calculation
Kinase reaction products were loaded on SDS gels and transferred to nitrocel-
lulose membranes. Membranes were stained with Amido black 10B, dried and
exposed to X-ray film. The relative phosphorylation score (PR-score) was
calculated from ratio of the radioactive signal from the autoradiograph [32P]
and the amount of respective fusion protein from the membrane (AB) accord-
ing to the following formula: PR-score =
32PS/ABS 3 ABRB1/
32PRB1 3 100%,
were S is the substrate, and RB1 the positive control.Quantification of In Vivo Phosphorylation Sites
by Mass Spectrometry
FLAG-FOXM1 was immunoprecipitated from HeLa cells and digested with
LysC. Resulting peptides were incubated with amino reactive tandem mass
tag reagents (TMT) and assigned with different mass tags. Samples were
analyzed by mass spectrometry, and TMT reporter ion intensities normalized
to the accumulation time of each MS3 spectrum.Gene Expression Analysis
Total RNAwas isolated from cells using the RNeasy kit (QIAGEN), and reverse-
transcribed with the ABI reverse transcription kit. Biotin-labeled cDNA was
hybridized to Affymetrix human 1.0 exon arrays, and derived CEL files were
analyzed with Partek’s Genomics Suite software (Partek, St. Louis, MO).ACCESSION NUMBERS
Exon array data were deposited in the NCBI Gene Expression Omnibus (GEO)
database (GSE32182).CanSUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, Supplemental Experimental
Procedures, and one table and can be found with this article online at
doi:10.1016/j.ccr.2011.10.001.
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